BPL-003 Phase 3 Runway: Why I’m Taking a Long on ATAI Ahead of Q2 Trial Kickoff
AtaiBeckley (ATAI) is a clinical-stage psychedelics-focused biotech with Phase 3 momentum for BPL-003 (mebufotenin nasal spray) in treatment-resistant depression. With Phase 2a/2b data showing rapid, durable responses, FDA alignment, a planned Phase 3 start in Q2 2026, and $220.7M in runway into early 2029, I see an asymmetric risk/reward for a lon…